PRX-105 is a plant cell-expressed PEGylated recombinant human Acetylcholinestrase (AChE) for potential use in the biodefense arena as a therapeutic and prophylactic countermeasure for nerve agents attack. PRX-105 functions as a natural "bioscavenger,” like a sponge, to bind poisons before they cause neurological damage. Protalix has also demonstrated that PRX-105 may hold a potential role in the treatment of Parkinson’s disease. This development program is under license agreement with Yissum Research and Development, the technology transfer arm of the Hebrew University of Jerusalem, Israel, and with the Boyce Thompson Institute, Inc., affiliated with Cornell University.
PRX-105 Clinical Status:
Protalix has completed a Phase 1 clinical trial of PRX-105, establishing the pharmacokinetics of the protein and demonstrating that single dose, intravenous administration of PRX-105 has a favorable safety profile and is well tolerated in healthy adults. Preclinical studies have established that PRX-105 protects against exposure to nerve gas agent analogs in both prophylactic and post-exposure settings, and have also demonstrated its promising biochemical and cellular biological activity. The Company is preparing further preclinical efficacy studies of PRX-105, and is also pursuing grants from civil and military organizations to support the further development of this program.